NT5E抗体

+ +

•  

   

     Black line: Control Antigen (100 ng); Purple line: Antigen(10ng); Blue line: Antigen (50 ng); Red line: Antigen (100 ng);    

  
  

•  

   

     Western blot analysis using NT5E mouse mAb against A431 (1) cell lysate.    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human bladder cancer tissues using NT5E mouse mAb with DAB staining.    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human esophagus cancer tissues using NT5E mouse mAb with DAB staining.    

  
  

NT5E, also known as CD73 or ecto-5'-nucleotidase, is a membrane-bound glycoprotein that functions as an ectoenzyme. It catalyzes the conversion of extracellular adenosine monophosphate (AMP) to adenosine, a key immunosuppressive molecule in the tumor microenvironment. This enzyme plays a critical role in purine metabolism and is expressed in various cell types, including immune cells (T cells, B cells), endothelial cells, and cancer cells. Its overexpression in multiple cancers (e.g., melanoma, breast, lung) correlates with tumor progression, immune evasion, angiogenesis, and metastasis by elevating adenosine levels that suppress anti-tumor T-cell responses via A2A adenosine receptor signaling.

NT5E antibodies are therapeutic tools designed to block CD73 enzymatic activity or disrupt its protein-protein interactions. By inhibiting adenosine production, these antibodies aim to counteract immunosuppression, enhance anti-tumor immunity, and synergize with checkpoint inhibitors (e.g., anti-PD-1/PD-L1). Several monoclonal antibodies (e.g., oleclumab, CPI-006) have entered clinical trials, showing potential in reducing tumor growth and improving immune infiltration. Challenges include managing compensatory pathways, biomarker identification, and minimizing off-target effects. Research continues to optimize antibody specificity, combination strategies, and patient stratification for precision oncology applications.